DK2454266T3 - 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaen-citratsalt - Google Patents

9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaen-citratsalt

Info

Publication number
DK2454266T3
DK2454266T3 DK10737645.1T DK10737645T DK2454266T3 DK 2454266 T3 DK2454266 T3 DK 2454266T3 DK 10737645 T DK10737645 T DK 10737645T DK 2454266 T3 DK2454266 T3 DK 2454266T3
Authority
DK
Denmark
Prior art keywords
nonaen
hexacosa
trioxa
tetracyclo
triaza
Prior art date
Application number
DK10737645.1T
Other languages
Danish (da)
English (en)
Inventor
Brian Dymock
Cheng Hsia Angeline Lee
Anthony Deodaunia William
Original Assignee
Cell Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapeutics Inc filed Critical Cell Therapeutics Inc
Application granted granted Critical
Publication of DK2454266T3 publication Critical patent/DK2454266T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK10737645.1T 2009-07-15 2010-07-14 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaen-citratsalt DK2454266T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22560909P 2009-07-15 2009-07-15
PCT/SG2010/000265 WO2011008172A1 (en) 2009-07-15 2010-07-14 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt

Publications (1)

Publication Number Publication Date
DK2454266T3 true DK2454266T3 (da) 2013-09-08

Family

ID=42790728

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10737645.1T DK2454266T3 (da) 2009-07-15 2010-07-14 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaen-citratsalt

Country Status (18)

Country Link
US (1) US9062074B2 (https=)
EP (1) EP2454266B1 (https=)
JP (2) JP6013911B2 (https=)
CN (1) CN102762577B (https=)
AR (2) AR077483A1 (https=)
BR (1) BR112012000750B1 (https=)
CA (1) CA2768210C (https=)
DK (1) DK2454266T3 (https=)
ES (1) ES2429525T3 (https=)
HR (1) HRP20130941T1 (https=)
MX (1) MX2012000680A (https=)
PL (1) PL2454266T3 (https=)
PT (1) PT2454266E (https=)
RU (1) RU2543721C2 (https=)
SI (1) SI2454266T1 (https=)
SM (1) SMT201300112B (https=)
TW (1) TWI537276B (https=)
WO (1) WO2011008172A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113559075A (zh) 2014-11-17 2021-10-29 康泰科思特生物制药公司 奥那司酮延长释放组合物和方法
AU2016326657B2 (en) 2015-09-25 2019-10-24 Context Biopharma, Inc. Methods of making onapristone intermediates
EP3389632A4 (en) 2015-12-15 2019-11-06 Context Biopharma Inc. AMORPHIC ONAPRISTON COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
WO2018102369A1 (en) 2016-11-30 2018-06-07 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY110603A (en) * 1993-05-27 1998-08-29 Novartis Ag Tetrahydropyran derivatives
WO2004078682A2 (en) * 2003-03-05 2004-09-16 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
NZ568325A (en) 2005-11-16 2011-05-27 S Bio Pte Ltd Macrocyclic oxygen linked pyrimidine derivatives

Also Published As

Publication number Publication date
CA2768210A1 (en) 2011-01-20
CA2768210C (en) 2017-08-15
EP2454266A1 (en) 2012-05-23
CN102762577A (zh) 2012-10-31
AR114987A2 (es) 2020-11-11
RU2012105044A (ru) 2013-08-20
BR112012000750B1 (pt) 2021-05-25
JP2015164941A (ja) 2015-09-17
TWI537276B (zh) 2016-06-11
JP2012533539A (ja) 2012-12-27
AR077483A1 (es) 2011-08-31
SMT201300112B (it) 2013-11-08
RU2543721C2 (ru) 2015-03-10
SI2454266T1 (sl) 2013-10-30
BR112012000750A2 (pt) 2016-08-09
ES2429525T3 (es) 2013-11-15
BR112012000750A8 (pt) 2018-02-06
US20120196876A1 (en) 2012-08-02
HRP20130941T1 (hr) 2013-11-08
CN102762577B (zh) 2015-01-07
JP6013911B2 (ja) 2016-10-25
WO2011008172A1 (en) 2011-01-20
EP2454266B1 (en) 2013-07-10
US9062074B2 (en) 2015-06-23
MX2012000680A (es) 2012-02-28
HK1178159A1 (en) 2013-09-06
PT2454266E (pt) 2013-10-10
TW201107336A (en) 2011-03-01
PL2454266T3 (pl) 2014-01-31

Similar Documents

Publication Publication Date Title
NL301021I2 (nl) talazoparib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout.
AP2012006216A0 (en) Benzimidazole-imidazole derivatives.
AP2011005788A0 (en) Sulfonamide derivatives.
BRPI1011414A2 (pt) "método."
ZA201205788B (en) 1,2,4-triazine-4-amine derivatives
BR112012003704A2 (pt) derivados de 3-amino-5-fenil-5,6-di-hidro-2h[1,4]oxazina
BRPI0919948A2 (pt) Pirido[4,3-b]indois contendo porções rígidas
BRPI1006113A2 (pt) "derivado de piridina".
HRP20150107T1 (xx) Derivati dioksabiciklo[3.2.1]oktan-2,3,4-triola
BRPI1106091A2 (pt) "método de solda."
UY33125A (es) Diaza-espiro-[5,5]-undecanos
ZA201206630B (en) Hetaryl-[1,8]naphthyridine derivatives
ZA201404074B (en) 6-difluoromethyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives
BRPI0917446A2 (pt) derivados de acilaminobenzamida.
ZA201204135B (en) 3,4,4a,10b-tetrahydro-1h-thiopyrano-[4.3-c]isoquinoline derivatives
BRPI1016192A2 (pt) derivados de soxazol.
DK2442870T3 (da) Pyrazinooxazepin-derivater.
IL289379A (en) Citrate salt of 11-(2-pyrrolidin-1-yl-ethoxy)-19,14-dioxa-26,7,5-triaza-tetracyclo[1.1.3.19(6,2)1(12,8)]hepatacosa- 1(25),2(26),12,10,8,5,3(27)j23,21,16–Decan
IL225189A0 (en) History 1,4 – oxazepene
BRPI1011014A2 (pt) método de produção.
IT1397021B1 (it) Carrello per rimorchi.
DK2454266T3 (da) 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaen-citratsalt
AP2010005479A0 (en) Phospohorous pentoxide producing methods.
PL2603512T3 (pl) Pochodne 6,7-dihydro-3h-oksazolo[3,4-a]pirazyno-5,8-dionu
BR112013011418A8 (pt) derivado de pirazino [2,3-d] isoxadol